NCT03244072View on ClinicalTrials.gov

Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery

PHASE2/PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

60,000

Participants

Timeline

Start Date

June 1, 2026

Primary Completion Date

October 31, 2030

Study Completion Date

October 31, 2031

Conditions
Endophthalmitis
Interventions
DRUG

Moxifloxacin

Intracameral injection

DRUG

Placebo

intracameral injection

Trial Locations (1)

84790

Zion Eye Institute, St. George

All Listed Sponsors
lead

Jason Ahee, M.D.

INDUSTRY

NCT03244072 - Safety and Efficacy of Intracameral Zimoxin for Prevention of Endophthalmitis After Cataract Surgery | Biotech Hunter | Biotech Hunter